Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone–Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist

The adjusted incidence of MACE was higher for men treated with the GnRH antagonist compared to the LHRH agonists. The demographic and risk factors with the greatest impact on MACE risk were higher age, baseline metastasis, oncology (vs urology) setting, personal MACE history, antagonist (vs agonist), tobacco history, White (vs Black) race, and lower BMI.